麗珠醫藥(01513.HK)同意控股附屬公司開展期貨套期保值業務
格隆匯5月7日丨麗珠醫藥(01513.HK)公佈,於2020年5月7日召開的董事會審議通過《關於控股附屬公司開展期貨套期保值業務的議案》,經與會董事認真審議,同意控股附屬公司麗珠集團新北江製藥股份有限公司、麗珠集團福州福興醫藥有限公司、麗珠集團(寧夏)製藥有限公司及四川光大製藥有限公司開展商品期貨套期保值業務,品種只限於與公司生產經營所需主要原材料相關的期貨品種,如玉米澱粉和白糖等,不得從事以投機為目的的期貨交易行為。計劃投入期貨套期保值業務的保證金總額不超過人民幣2,000.00萬元,有效期自公司董事會審議通過之日起12個月內。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.